

Docket No.: 22122-00009-US1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Florian V. Mulbe et al.

Application No.: 10/729,830

Confirmation No.: 8653

Filed: December 5, 2003

Art Unit: 1636

For: PHARMACEUTICAL COMPOSITION
CONTAINING A STABILISED mRNA
OPTIMISED FOR TRANSLATION IN ITS
CODING REGIONS

Examiner: J. A. Dunston

SECOND DECLARATION OF DR. INGMAR HOERR

Dr. Ingmar Hoerr deposes and states as follows:

1. I am an inventor named on the above-captioned patent application and I am affiliated with the assignee of the application. I provided a previous declaration in connection with this application, which was dated October 10, 2006. My scientific background and technical qualifications are provided in that prior declaration.

2. Additional experiments have been performed under my direction and control, the results of which are reported in this second declaration.

3. The experiments reported in this second declaration were directed towards investigating the anti-tumour response obtained upon vaccination of an animal by injection of either wild-type mRNA encoding a human tumour antigen, or, for comparison, an mRNA encoding the same tumour antigen but which had been modified to contain a higher content of GC relative to wild type, in accordance with the disclosure of this patent application.

4. Two types of experiments were performed:

U.S. Application Serial No. 10/729,830
Second Declaration of Dr. Ingmar Hoerr

- a. Using tumour challenge experiments, we investigated whether tumour growth could be reduced by vaccination with GC-enriched mRNA in comparison to vaccination using the respective wild-type mRNA coding for the human tumour antigens Survivin, GP100 and TRP-2; and
- b. Using ELISPOT experiments, we investigated whether vaccination with GC-enriched mRNA coding for the tumour antigens MAGE-A2, MAGE-C2 and STEAP leads to the induction of more tumour antigen specific cytotoxic T-cells as compared to vaccination with the corresponding wild type mRNAs.

5. The results of our experiments are shown in the graphs provided below. The experimental methods are described in the text which follows. Attached to this declaration are the nucleotide sequences of the mRNAs which were used in the experiments.

6. To summarize the results of the experiments:

- a. In the tumour challenge experiments, it was demonstrated that tumour growth is reduced more efficiently by vaccination with GC-enriched mRNA, as compared with the corresponding wild type mRNA coding for the human tumour antigens Survivin, GP100 and TRP-2. The tumour model used in these experiments is an accepted model for determining vaccine activity to inhibit growth of human tumours.
- b. The ELISPOT experiments showed that vaccination with GC-enriched mRNA coding for the tumour antigens MAGE-A2, MAGE-C2 and STEAP leads to the induction of more tumour antigen specific cytotoxic T- cells than does vaccination with the corresponding wild-type mRNA. These results are significant, since it has been shown in recent years that induction of tumour antigen-specific cytotoxic T-cells is necessary for induction of immunity against tumour cells *in vivo*. The ELISPOT data confirms that GC-

U.S. Application Serial No. 10/729,830
Second Declaration of Dr. Ingmar Hoerr

enriched mRNA coding for a human tumour antigen is more potent for tumour vaccination than the corresponding wild type mRNA.

7. The ELISPOT assay is described in Janeway, Charles A.; Travers, Paul; Walport, Mark; Shlomchik, Mark; Immunobiology; New York and London: Garland Science; 2001, and is a modification of the ELISA antigen-capture assay. The ELISPOT assay is recognized to be a useful tool for measuring the frequency of T-cell responses. In the method, populations of T cells are stimulated with the antigen of interest (in this case, re-stimulation with an antigen-specific peptide library, as described *infra*), and are then allowed to settle onto a plastic plate coated with antibodies to the cytokine which is to be assayed (here, INF-gamma). If an activated T cell is secreting the cytokine, it is captured by the antibody on the plastic plate. After an appropriate period of time, the cells are removed, and a second antibody which is reactive to the cytokine is added to the plate, which reveals a circle of bound cytokine surrounding the position of each activated T cell. By counting each spot, and by knowing the number of T cells originally added to the plate, one may readily calculate the frequency of T cells which are secreting the cytokine. In this manner, we used the ELISPOT assay to quantify the number of antigen specific cytotoxic T cells which were present in the experimental animals following vaccination with mRNA encoding for several tumour antigens.

8. The murine B16 melanoma tumour model has been known and used for several years, having been described by Fidler, I.J., Selection of successive tumour lines for metastasis. Nat. New Biol., 242:148-149, 1973. B16 melanoma cells were isolated from C57BL/6 mice and provide a syngenic tumour model for evaluating the efficacy of anti-tumour vaccines. Since there is no *in vivo* human model available for use by workers in this field, this model is an important and art-recognized model for evaluating human tumour vaccination strategies.

9. Recombinant plasmid DNA was linearized and subsequently *in vitro* transcribed using T7 RNA polymerase. The DNA template was then degraded by DNaseI digestion. The mRNA was recovered by LiCl precipitation and further

U.S. Application Serial No. 10/729,830
Second Declaration of Dr. Ingmar Hoerr

cleaned by HPLC extraction (Pure Messenger®, CureVac GmbH, Tübingen, Germany).

10. The animals used were C57BL/6 mice, in groups of 5 mice per group. The tumour cells used were B16F10 melanoma cells. Immunization was performed with 20 µg mRNA (10 µg per ear) complexed with protamine (RNA:protamine (8:1)) which was injected intradermally in the mice 8 times over a period of 3 weeks.

11. For the tumor challenge experiments, the mice were divided into groups which received vaccination with the following mRNAs:

Groups:

- Survivin wt
- Survivin GC
- GP100 wt
- GP 100 GC
- TRP2 wt
- TRP2 GC

One week after the last immunization, 4×10^5 B16 melanoma cells were injected subcutaneously in the mice. For the next 10-17 days tumour volume was determined.

Figure 4 shows the results of the tumour challenge experiment with B16 melanoma cells in C57BL/6 mice, one week after the last vaccination with wild-type mRNA (Survivin wt) or GC-enriched mRNA encoding Survivin (Survivin GC). Tumour cells were implanted and tumour growth was observed for 10 days.

Figure 5 shows a tumour challenge experiment with B16 melanoma cells in C57BL/6 mice, one week after the last vaccination with wild-type mRNA (GP100 wt) or GC-enriched mRNA (GP100 GC). Tumour cells were implanted and tumour growth was observed for 17 days.

Figure 6 shows a tumour challenge experiment with B16 melanoma cells in C57BL/6 mice, one week after the last vaccination with wild type

U.S. Application Serial No. 10/729,830
Second Declaration of Dr. Ingmar Hoerr

mRNA (TRP2 wt) or GC-enriched mRNA (TRP2 GC). Tumour cells were implanted and tumour growth was observed for 17 days.

12. The results depicted in Figures 4-6 are, in my opinion, predictive of the utility of GC-enriched mRNA encoding a human tumor antigen to treat tumours in a human patient. B16 melanoma cells express endogenously the tumour antigens Survivin, GP100 and TRP2. Accordingly, those antigens were chosen for the vaccination experiments. Mice receiving prophylactic vaccination with wild type or GC-enriched mRNA coding for these antigens were compared, and the results reflect that mice which were vaccinated with GC-enriched mRNA showed a reduced increase in tumour growth as compared to the mice vaccinated with wild type mRNA. These results suggest that vaccination with GC-enriched mRNA coding for a human tumour antigen will be more effective for vaccination than wild type mRNA.

13. For the ELISPOT experiments, the mice were divided into groups which received vaccination with the following mRNAs:

Groups:

- MAGE-A2 wt
- MAGE-A2 GC
- MAGE-C2 wt
- MAGE-C2 GC
- STEAP wt
- STEAP GC

Two weeks after the last vaccination, the mice were sacrificed, the spleens were removed, and the splenocytes were isolated. For re-stimulation, 3×10^7 splenocytes were incubated for 5 days with an antigen-specific peptide library (1 μ g/ml per peptide) in presence of IL-2 (30 U/ml). To determine an antigen-specific cellular immune response, IFN γ secretion was measured after re-stimulation with peptide. For detection of IFN γ a coat multiscreen plate (Millipore) was incubated overnight with coating buffer (0,1 M Carbonat-Bicarbonat Buffer pH 9,6, 10,59 g/l Na $_2$ CO $_3$, 8,4g/l NaHCO $_3$) comprising

U.S. Application Serial No. 10/729,830
Second Declaration of Dr. Ingmar Hoerr

antibody against IFN γ (BD Pharmingen, Heidelberg, Germany). After coating, effector cells (5×10^5 /well) were incubated with the antigen-specific peptide library, an unspecific control peptide, DMSO or medium as control for 24h in the plate. Subsequently the plate was washed with 1xPBS and incubated with a biotin-coupled secondary antibody. After washing with 1xPBS/0,05% Tween-20 the substrate (5-Bromo-4-Chloro-3-Indolyl Phosphate/Nitro Blue Tetrazolium Liquid Substrate System from Sigma Aldrich, Taufkirchen, Germany) was added to the plate and the conversion of the substrate could be detected visually.

Figure 1 shows the results of the ELISPOT assay measuring the IFN γ secretion of splenocytes of mice which were vaccinated respectively with wild type mRNA (MAGE-A2 wt) or GC-enriched mRNA (MAGE-A2 GC) coding for MAGE-A2. The secretion of IFN γ by splenocytes was measured after re-stimulation with a MAGE-A2 specific peptide library (antigen-specific peptide library), DMSO, an unspecific control peptide library (control peptide) or medium as control.

Figure 2 shows the results of the ELISPOT assay measuring the IFN γ secretion of splenocytes of mice which were vaccinated respectively with wild type mRNA (MAGE-C2 wt) or GC-enriched mRNA (MAGE-C2 GC) coding for MAGE-C2. The secretion of IFN γ of splenocytes was measured after re-stimulation with a MAGE-C2 specific peptide library (antigen-specific peptide library), DMSO, an unspecific control peptide library (control peptide) or medium as control.


Figure 3 shows the results of the ELISPOT assay measuring the IFN γ secretion of splenocytes of mice which were vaccinated respectively with wild type mRNA (STEAP wt) or GC-enriched mRNA (STEAP GC) coding for STEAP. The secretion of IFN γ of splenocytes was measured after re-stimulation with a STEAP specific peptide library (antigen-specific peptide library), DMSO, an unspecific control peptide library (control peptide) or medium as control.

U.S. Application Serial No. 10/729,830
Second Declaration of Dr. Ingmar Hoerr

14. The results presented in Figures 1-3 illustrate that vaccination with GC-enriched mRNA coding for a tumour antigen initiates a stronger anti-tumor cytotoxic T cell immune response than does vaccination with wild type mRNA. As persons working in this art would appreciate, a stronger cytotoxic T cell immune response is likely to correlate with improved anti-tumour efficacy *in vivo*.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of this application of any patent issued thereon.

Date: 14-Oct-2008



Dr. Ingmar Hoerr

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5





Fig. 6



Sequences:

MRNA HsTRP2(wt)-ag-A70

GGGAGACAAGCTTACCatgagcccccttgggtgggggttctgctcagttgctgggctgcaaaatcctgccaggagcccagggtcag
ttccccgagtgctgcatgacgggtggacagcctagtgacaaggagtgctgccacgcctgggtgcagagtcggccaatgtctgtggctctcag
caaggccgggggcagtgacagaggtgagagccgacacaaggccctggagtggtccctacatcctacgaaaccaggatgacccgtgagct
gtggccaagaaaattctccaccggacctgcaagtgcacaggaaactttgccggctataattgtggagactgcaagtttgctggaccggctcc
aactgcgagcggaagaaccaccagtgattcggcagaacatccattccttgagtcctcaggaaagagagcagttctgggcgccctagatctc
gcgaagaagagagtacaccccgactacgtgatcaccacacaacactggctgggcctgctgggccaatggaaccagccgcagtttgcca
actgcagtgttatgatgtttgtgtggctccattattctgttagagatacattattaggaccaggacgcccctacagggccatagattctcacatc
aaggacctgcattgttacctggcaccgggtaccattgtgtgtctggaagagatctccagcgactcattggcaatgagtcctttgctttgccctact
ggaactttgccactgggaggaacgagtgatgtgtgtacagaccagctgtttggggcagcgagaccagacgatccgactctgattagtcgga
actcaagatttccagctgggaaactgtctgtgatagcttgatgactacaaccacctggtcaccttgcaatggaacctatgaaggtttgctga
gaagaaatcaaatgggaagaaacagcatgaaattgccaacctaaagacatacagattgcctgtctcctcagaagttgacaatcctccctt
cttcagaactctaccttcagttcaggaatgctttggaaggggttgataaagcagatgggactctggattctcaagtatgagccttcataattgtt
tcatctctctgaacgggacaaacgctttgccacattcagccgcaatgatccattttgtgttctctcattccttactgatccatctttagtgagtg
gatgaaaagatttaacctcctgcagatgcctggcctcaggagctggccctattggtcacaatcggaatgacaacatggttccttctccctcca
gtgactaatgaagaactcttttaacctcagaccaactggctacagctatgccatcgatctgccagtttcagttgaagaaactccaggttgccca
caactctctagtagtcatgggaacactgggtggctttgggtgtctttgtgctgttggctttcttcaatagaagacttcgaaaaggatatacacc
ctaattggagacacatttaagcagcaagagatacacagaagaagcctagCCACTAGTGACTGACTAGCCCCGTGGGCC
TCCCAACGGGGCCCTCCTCCCCTCCTTGACCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AACTGCAGGTGCACTCTAGAGGATCCCCGGGTA
CCGAGCTCGAATT

MRNA HsTRP2(GC)-muag-A70-C30

GGGAGAAAGCTTACCATGAGCCCCCTGTGGTGGGGCTTCCTCCTGTCCTGCCTGGGGTGCAAGA
TCCTCCCGGGCGCCCAGGGGCAGTTCCTCCCGGGTGTGCATGACCGTCGACAGCCTGGTGAACA
AGGAGTGCTGCCCCCGCCTGGGCGCCGAGTCCGCGAACGTGTGCGGGAGCCAGCAGGGCCGG
GGCCAGTGACCGAGGTCCGCGCCGACACGCGGCCCTGGTCCGGGCCGTACATCCTCCGCAAC
CAGGACGACCGGGAGCTGTGGCCCCGCAAGTTCTTCCACCGGACCTGCAAGTGACCGGCAAC
TTCGCCGGGTACAAGTGGCGGACTGCAAGTTCGGGTGGACCGGCCCAACTGCGAGCGCAAG
AAGCCCCCGGTGATCCGGCAGAACATCCACAGCCTGTCCCCCAGGAGCGCGAGCAGTTCCTC
GGCGCCCTGGACCTGGCCAAGAAGCGGGTGCACCCCGACTACGTATCACGACCCAGCACTGG
CTCGGGCTGCTGGGCCCCAACGGGACCCAGCCGAGTTCGCGAACTGCAGCGTGTACGACTTC
TTCGTGTGGCTCCACTACTACTCCGTCCGCGACACCCTGCTGGGCCCCGGCCGGCCCTACCGC
GCCATCGACTTCAGCCACCAGGGGCCCGCCTTCGTGACGTGGCACCGGTACCACTCCTGTGC
CTGGAGCGCGACCTCCAGCGGCTGATCGGCAACGAGTCCTTCGCCCTGCCGTACTGGAATTC
GCGACCGGGCGCAACGAGTGCGACGTGTGCACCGACCACTCTTCGGCGCCGCCCGGCCCGA
CGACCCACCCCTGATCAGCCGCAACTCCCGGTTCACTCCTGGGAGACGGTCTGCGACAGCCT

GGACGACTACAACCACCTCGTGACCCTGTGCAACGGGACCTACGAGGGCCTGCTCCGGCGCAA
CCAGATGGGCCGGAACCTCCATGAAGCTGCCCACCCTGAAGGACATCCGCGACTGCCTCAGCCT
GCAGAAGTTTCGACAACCCGCCCTTCTTCCAGAAGTCCACGTTACGTTCCGGAACGCCCTGGAG
GGGTTTCGACAAGGCCGACGGCACCCTCGACAGCCAGGTGATGTCCCTGCACAACCTGGTCCAC
AGCTTCCTCAACGGGACCAACGCGCTGCCCCACTCCGCCGCCAACGACCCCATCTTCGTGGTGC
TGCACAGCTTCACCGACGCCATCTTCGACGAGTGGATGAAGCGCTTCAACCCGCCCGCCGACGC
GTGGCCCCAGGAGCTCGCCCCCATCGGCCACAACCGGATGTACAACATGGTCCCGTTCTTCCCG
CCCGTGACGAACGAGGAGCTGTTCTGACCTCCGACCAGCTCGGGTACAGCTACGCCATCGACC
TGCCGGTGTCCGTGAGGAGACCCCCGGCTGGCCGACCACGCTGCTGGTGGTGGTGGTGGTGGT
TCGTGCCCCCTGGTGGGGCTGTTCTGTCCTCTGTCCTTCTGTCAGTACCGCCGGCTCCGCAAGG
GCTACACCCCCCTGATGGAGACCCACCTGAGCTCCAAGCGGTACACGGAGGAGGCGTGACCAC
TAGTTATAAGACTGACTAGCCCGATGGGCCTCCCAACGGGCCCTCCTCCCCCTCCTTGCACCGAG
ATTAATAAA
AATATCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCTCTAGACAATTGGAATT

MRNA HsSILV-isoCRA_c(wt)-ag-A70 (SILV = GP100)

GGGAGACAAGCTAcacaATGGATCTGGTGCTAAAAAGATGCCTTCTTCATTTGGCTGTGATAGGTG
CTTTGCTGGCTGTGGGGGCTACAAAAGTACCCAGAAACCAGGACTGGCTTGGTGTCTCAAGGCA
ACTCAGAACCACAAAGCCTGGAACAGGCAGCTGTATCCAGAGTGGACAGAAGCCAGAGACTTGAC
TGCTGGAGAGGTGGTCAAGTGTCCCTCAAGGTCAGTAATGATGGGCCTACACTGATTGGTGCAA
ATGCCTCCTTCTCTATTGCCTTGAACCTCCCTGGAAGCCAAAAGGTATTGCCAGATGGGCAGGTT
ATCTGGGTCAACAATACCATCATCAATGGGAGCCAGGTGTGGGGAGGACAGCCAGTGTATCCCC
AGGAAACTGACGATGCCTGCATCTTCCCTGATGGTGGACCTTGCCCATCTGGCTCTTGGTCTCAG
AAGAGAAGCTTTGTTTATGTCTGGAAGACCTGGGGCCAATACTGGCAAGTTCTAGGGGGCCAG
TGTCTGGGCTGAGCATTGGGACAGGCAGGGCAATGCTGGGCACACACACCATGGAAGTGACTGT
CTACCATCGCCGGGGATCCCGGAGCTATGTGCCTCTTGCTCATTCCAGCTCAGCCTTCACCATTA
CTGACCAGGTGCCTTTCTCCGTGAGCGTGTCCAGTTGCGGGCCTTGGATGGAGGGAACAAGCA
CTTCTGAGAAATCAGCCTCTGACCTTTGCCCTCCAGCTCCATGACCCAGTGGCTATCTGGCTG
AAGCTGACCTCTCCTACACCTGGGACTTTGGAGACAGTAGTGGAACCCTGATCTCTCGGGCACTT
GTGGTCACTCATACTTACCTGGAGCCTGGCCCAGTCACTGCCAGGTGGTCTCTGACGGCTGCCA
TTCCTCTACCTCCTGTGGCTCCTCCCCAGTTCCAGGCACCACAGATGGGCACAGGCCAACTGC
AGAGGGCCCTAACACCACAGCTGGCCAAGTGCCTACTACAGAAAGTTGTGGGTACTACACCTGGT
CAGGCGCCAACCTGCAGAGCCCTCTGGAACCACATCTGTGCAGGTGCCAACCCTGAAGTCATAA
GCACTGCACCTGTGCAGATGCCAAGTGCAGAGAGCACAGGTATGACACCTGAGAAGGTGCCAGT
TTCAGAGGTCATGGGTACCACACTGGCAGAGATGTCAACTCCAGAGGCTACAGGTATGACACCT
GCAGAGGTATCAATTGTGGTGCTTTCTGGAACCACAGCTGCACAGGTAACAACCTACAGAGTGGGT
GGAGACCACAGCTAGAGAGCTACCTATCCCTGAGCCTGAAGGTCCAGATGCCAGCTCAATCATG
TCTACGGAAAGTATTACAGGTTCCCTGGGCCCCCTGCTGGATGGTACAGCCACCTTAAGGCTGG
TGAAGAGACAAGTCCCCCTGGATTGTGTTCTGTATCGATATGGTTCCTTTTCCGTACCCCTGGAC

ATTGTCCAGGGTATTGAAAGTGCCGAGATCCTGCAGGCTGTGCCGTCCGGTGAGGGGGATGCAT
TTGAGCTGACTGTGTCTGCTGCCAAGGCGGGCTGCCCAAGGAAGCCTGCATGGAGATCTCATCGCC
AGGGTGCCAGCCCCCTGCCAGCGGCTGTGCCAGCCTGTGCTACCCAGCCCAGCCTGCCAGCT
GGTCTGCACCAGATACTGAAGGGTGGCTCGGGGACATACTGCCTCAATGTGTCTCTGGCTGAT
ACCAACAGCCTGGCAGTGGTCAGCACCCAGCTTATCATGCCTGtgctgggattctctcacaGGTCAAGAA
GCAGGCCTTGGGCAGGTTCCGCTGATCGTGGGCATCTTGCTGGTGTGATGGCTGTGGTCCTTG
CATCTCTGATATATAGGCGCAGACTTATGAAGCAAGACTTCTCCGTACCCAGTTGCCACATAGC
AGCAGTCACTGGCTGCGTCTACCCCGCATCTTCTGCTCTTGTCCTTGGTGAAGAATAGCCCCCT
CCTCAGTGGGCAGCAGGTCTGAgtacactagtgactgactagcccgtgggctcccaacgggcccctctccctccttgacc
aaaaaaaaaaaaaaaaAA
tgcaGGTCGACTCTAGAGGATCCCCGGGTACCGAGCTCGAATT

MRNA HsSILV(GC)-muag-A70-C30

GGGAGAAAGCTTACCATGGACCTGGTGCTCAAGCGGTGCCTGCTGCACCTCGCCGTCATCGGC
GCCCTGCTGGCGGTGGGGGCCACCAAGGTGCCCCGCAACCAGGACTGGCTCGGCGTCAGCCG
GCAGCTGCGCACCAAGGCCTGGAACCGGCAGCTGTACCCGGAGTGGACGGAGGCCAGCGCC
TCGACTGCTGGCGGGGCGGGCAGGTGTCCCTGAAGGTGAGCAACGACGGGCCACCCCTGATCG
GCGCCAACGCGTCTTCAGCATCGCCCTCACTTCCCCGGCTCCCAGAAGGTCCTGCCCGACG
GGCAGGTGATCTGGGTGAACAACACCATCATCAACGGCAGCCAGGTCTGGGGCGGGCAGCCGG
TGTACCCCCAGGAGACCGACGACGCCTGCATCTTCCCCGACGGGGGCCCTGCCCGTCCGGCA
GCTGGTCCCAGAAGCGCAGCTTCGTGTACGTCTGGAAGACGTGGGGGCAGTACTGGCAGGTGC
TGGGCGGGGCCCGTGTCCGGCCTCAGCATCGGCACCGGGCGGGCCATGCTGGGCACCCACACC
ATGGAGGTCACGGTGTACCACCGCCGGGGGTCCCGCAGCTACGTGCCCTGGCGCACTCCAGC
TCCGCCTTACCATCACCGACAGGTCCCCTTCAGCGTGTCCGTGAGCCAGCTCCGGGGCCCTGG
ACGGCGGGAACAAGCACTTCCTGCGCAACCAGCCGCTCACCTTCGCCCTGCAGCTGCACGACC
CCAGCGGCTACCTCGCCGAGGCGGACCTGTCTACACGTGGGACTTCGGCGACAGCTCCGGGA
CCCTGATCAGCCGGGCCCTCGTCTGTACCCACACCTACCTGGAGCCCGGGCCCGTGCAGGGCC
AGGTCTGTGCTGCAGGCCGCCATCCCGCTCACCTCCTGCGGGAGCTCCCCCGTCCCCGGCACCA
CCGACGGGCACCGCCCCACGGCGGAGGCCCCGAACACCACCGCCGGCCAGGTGCCACCACG
GAGGTGGTGGGCACCAACCCCGGGCAGGCCCCACCGCCGAGCCGAGCGGCACGACCTCCGT
GCAGGTGCCACCAACCGAGGTCATCAGCACGGCGCCCGTGCAGATGCCACCGCCGAGTCCAC
CGGGATGACCCCGGAGAAGGTGCCCGTCAGCGAGGTGATGGGCACGACCCTGGCCGAGATGTC
CACCCCGAGGCCACCGGGATGACCCCGGCCGAGGTGAGCATCGTCTGTCTGTCGGCACGAC
CGCGGGCCAGGTGACCACCACGGAGTGGGTGAGACCACCGCCCGGGAGCTCCCCATCCCCG
AGCCCGAGGGCCCGGACGCCAGCTCCATCATGAGCACCGAGTCCATCACGGGGAGCCTGGGCC
CCCTGCTCGACGGGACCGCGACCCTGCGCCTGGTGAAGCGGCAGGTGCCCTCGACTGCGTCC
TGTACCGCTACGGCAGCTTCTCCGTGACCTGGACATCGTGCAGGGCATCGAGAGCGCCGAGAT
CCTCCAGGCCGTCCCCTCCGGGGAGGGCGACGCCTTCGAGCTGACGGTGAGCTGCCAGGGCG
GGCTGCCGAAGGAGGCCTGCATGGAGATCTCCAGCCCCGGGTGCCAGCCCCCGCGCAGCGG

CTCTGCCAGCCGGTGCTGCCCTCCCCCGCCTGCCAGCTGGTCCTGCACCAGATCCTCAAGGGC
GGCAGCGGGACCTACTGCCTGAACGTGTCCCTGGCCGACACCAACAGCCTCGCCGTGGTCTCC
ACCCAGCTGATCATGCCCGGCCAGGAGGCCGGGCTGGGCCAGGTGCCGCTCATCGTGGGGATC
CTGCTGGTCCTCATGGCGGTGGTGCTGGCCAGCCTGATCTACCGCCGGCGGCTCATGAAGCAG
GACTTCTCCGTCCCCAGCTGCCCCACAGCTCCAGCCACTGGCTGCGCCTCCCCCGGATCTTCT
GCTCCTGCCCGATCGGCGAGAACAGCCCCCTGCTGAGCGGCCAGCAGGTGTGACCACTAGTTA
TAAGACTGACTAGCCCGATGGGCCTCCCAACGGGGCCCTCCTCCCCCTCCTTGCACCGAGATTAAT
AATATT
CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCTCTAGACAATTGGAATT

MRNA HsSurvivin(wt)-ag-A70

GGGAGACAAGCTTaccATGGGTGCCCCGACGTTGCCCCCTGCCTGGCAGCCCTTTCTCAAGGAC
CACCGCATCTCTACATTCAAGAACTGGCCCTTCTTGAGGGCTGCGCCTGCACCCCGGAGCGGA
TGGCCGAGGCTGGCTTCATCCACTGCCCCACTGAGAACGAGCCAGACTTGGCCAGTGTTTCTT
CTGCTTCAAGGAGCTGGAAGGCTGGGAGCCAGATGACGACCCCATAGAGGAACATAAAAAGCAT
TCGTCCGGTTGCGCTTTCCTTTCTGTCAAGAAGCAGTTTGAAGAATTAACCTTGGTGAATTTTG
AAACTGGACAGAGAAAGAGCCAAGAACAAAATTGCAAAGGAAACCAACAATAAGAAGAAAGAATT
TGAGGAAACTGCGAAGAAAGTGCGCCGTGCCATCGAGCAGCTGGCTGCCATGGATTGAccACTA
GTGACTGACTAGCCCGCTGGGCCTCCCAACGGGGCCCTCCTCCCCCTCCTTGCACCAAAAAAAAAA
AACTGCAGG
TCGACTCTAGAGGATCCCCGGGTACCGAGCTCGAATT

MRNA HsSurvivin(GC)-muag-A70-C30

GGGAGAAAGCTTaccATGGGCGCCCCCACCCTGCCGCCGGCCTGGCAGCCGTTCTCAAGGACC
ACCGCATCTCGACCTTCAAGAACTGGCCGTTCTTGAGGGCTGCGCGTGCACCCCGGAGCGGA
TGGCCGAGGCCGGCTTCATCCACTGCCCCACCGAGAACGAGCCGGACCTGGCCCAGTGCTTCT
TCTGCTTCAAGGAGCTGGAGGGCTGGGAGCCGGACGACGACCCGATCGAGGAGCACAAGAAGC
ACAGCAGCGGCTGCGCCTTCTGAGCGTGAAGAAGCAGTTCGAGGAGCTGACGCTCGGGGAGT
TCCTGAAGCTGGACCGGGAGCGGGCCAAGAACAAGATCGCGAAGGAGACCAACAACAAGAAGA
AGGAGTTTCGAGGAGACCGCCAAGAAGGTGCGGCGGGCCATCGAGCAGCTGGCCGCCATGGACT
gaccACTAGTTATAAGACTGACTAGCCCGATGGGCCTCCCAACGGGGCCCTCCTCCCCCTCCTTGA
CCGAGATTAATAA
AAAAAAATATTCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCTCTAGACAATTGGAATT

MRNA HsMageA2(wt)-ag-A70

GGGAGACAAGCTTaccatgcctcttgagcagaggagtcagcactgcaagcctgaagaaggccttgaggcccgaggagaggccctg
ggcctggtgggtgctgcaggctcctgctactgaggagcagcagaccgtcttctcttactctagtggaggtaccctgggggagggtgctgct
gccgactcaccgagtcctccccacagtcctcagggagcctccagcttctcgactaccatcaactacactcttggagacaatccgatggggct
ccagcaaccaagaagaggaggggccaagaatgttcccgacctggagtcagggtccaagcagcaatcagtaggaagatgggtgagttggt

tcattttctgtcctcaagatcagccaggagccggtcacaaaggcagaaatgctggagagtgctcagaaattgccaggacttcttcccg
gatcttcagcaaagcctccgagfacttgcagctggcttggcatcgagggtggaagtggccccatcagccacttgatccttgcacctgc
ctggcctctcctacgatggcctgctggcgacaatcaggtcatgccaaagacaggcctcctgataatcgtcctggccataatcgcaatagag
ggcgactgtccccctgaggagaaaatctgggaggagctgagtagtggagggtgttggagggaggaggacagtgtcttcgcacatccag
gaagctgctcatgcaagatctgtgcaggaaaactacctggagtaccggcagggtgcccggcagtgatcctgcatgctacgagttcctgtggg
tccaagggccctcattgaaaccagctatgtgaaagtcctgcaccatacactaaagatcggtggagaacctcacatttctacccacccctgcat
gaacgggcttggagagaggagaagagtaccACTAGTGACTGACTAGCCCGCTGGGCCTCCCAACGGGCCCC
TCCTCCCCTCCTTGACCAA
AAAAAAAAAAAAAAAAAAAAACTGCAGGTCGACTCTAGAGGATCCCCGGGTACCGAGCTCGAATT

MRNA HsMageA2(GC)-muag-A70-C30

GGGAGAAAGCTTACCATGCCCCCTGGAGCAGCGGAGCCAGCACTGCAAGCCGGAGGAGGGCCTC
GAGGCCCCGCGGGGAGGCCCTGGGCCTGGTGGGGGCGCAGGCCCCCGCCACCGAGGAGCAGC
AGACCGCCTCCAGCTCCAGCACGCTCGTCGAGGTGACCCTGGGCGAGGTGCCCGCCGCGGACT
CCCCCAGCCCGCCCCACTCCCCCAGGGGGCCAGCTCCTTCAGCACCACCATCACTACACGCT
GTGGCGGCAGTCCGACGAGGGCAGCTCCAACCAGGAGGAGGAGGGCCCCCGCATGTTCCCGG
ACCTCGAGAGCGAGTTCCAGGCCGCCATCTCCCGGAAGATGGTCGAGCTGGTGCACCTTCCTGCT
CCTGAAGTACCGCGCGCGGGAGCCCGTGACCAAGGCCGAGATGCTGGAGAGCGTCTCCGCAA
CTGCCAGGACTTCTTCCCCGTGATCTTCTCCAAGGCCAGCGAGTACCTGCAGCTGGTGTTCGGG
ATCGAGGTCTGGAGGTGGTCCCCATCTCCACCTCTACATCCTGGTGACCTGCCTGGGCCTCA
GCTACGACGGGCTGCTGGGCGACAACCAGGTGATGCCGAAGACCGGGCTCCTGATCATCGTCC
TGGCCATCATCGCCATCGAGGGCGACTGCGCGCCCCGAGGAGAAGATCTGGGAGGAGCTCAGCA
TGCTGGAGGTGTTGAGGGCCGGGAGGACTCCGTGTTGCCCCACCCCGCAAGCTGCTCATGC
AGGACCTGGTCCAGGAGAACTACCTGGAGTACCGGCAGGTGCCCGGGAGCGACCCGGCCTGCT
ACGAGTTCTCTGGGGCCCCCGCGCCCTGATCGAGACGTCTACGTGAAGGTCTGCACCACAC
CCTCAAGATCGGGGGCGAGCCCCACATCAGCTACCCGCCGCTGCACGAGCGGGCCCTGCGCGA
GGGCGAGGAGTGACCACTAGTTATAAGACTGACTAGCCCGATGGGCCTCCCAACGGGCCCCCTCT
CCCCTCCTTGACCGAGATTAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAATATCCCCCCCCCCCCCCCCCCCCCCCCCCCCCTCTAGACAATT
GGAATT

MRNA HsMageC2(wt)-ag-A70

GGGAGACAAGCTTACCatgctcccgttcaggcggtccattccgcaacgttgacaacgactccccgacctcagttgagttagaaga
ctgggtagatgcacagcatccacagatgaggaagaggaggaagcctcctccgcttctccactttgtacttagtattttccctcttcttcca
catcctcttctgattcttgggtgctgaggaggagggtgcctctggtgtgataccaaatctaccgagagcattccagtagtctccaca
gggtctccacagggtccttcccagagtcctctgagctcctgctgctccttcttcatggagctcattcagtgaggagtcacgagccagaaagg
ggaggatacaggcacctgtcagggcctgccagacagtgagtcctcttccatatacactagatgaaaagggtggccgagttagtgagttcctg
ctcctcaaatacgaagcagaggagcctgtaacagaggcagagatgctgatgattgtcatcaagtacaagattacttctgtgatactcaaga
gagcccgtagttcatggagcttcttggccttgcctgatagaagtgggcccgtaccactctgtgtgttggcaaacacagtaggcctcaccgat

gagggtagtgatgatgagggcatgcccgagaacagcctcctgattattattctgagtgatcttcataaagggaactgtgcctctgaggaggt
catctgggaagtgtgaatgcagtaggggtatatgtctgggaggagcacttcgtctatggggagcctagggagctcctcactaaagtgtgggtg
cagggacattacctggagtaicgggaggtgcccacagttctcctcatattatgaattcctgtgggtccaagagcccattcagaaagcatcaa
gaagaaagtactagagtttttagccaagctgaacaacactgttcctagttccttccatcctggtacaaggatgcttgaaagatgtggaagagag
agtcaggccacaattgataccgcagatgatgccactgtcatggccagtgaaagccctcagtgcatgtccagcaacgtctcctttctgagtgac
CACTAGTGA CTGACTAGCCCGCTGGGCCTCCCAACGGGCCCTCCTCCCCCTCCTTGACCAAAAAA
AACT
GCAGGTCGACTCTAG

MRNA HsMageA2(GC)-muag-A70-C30

GGGAGAAAGCTTACCATGCCCCGGTGGCCGGCTCCCCCTCCGGAACGTGGACAACGACAGC
CCCACCTCCGTGGAGCTGGAGGACTGGGTGACGCCAGCAGCCGACCGACGAGGAGGAGGA
GGAGGCCAGCTCCGCGAGCTCCACGCTCTACCTGGTGTTAGCCCCCTCCAGCTTCTCCACCAGC
TCCAGCCTGATCCTCGGGGGCCCCGAGGAGGAGGAGGTGCCCTCCGGGGTCATCCCGAACCTG
ACCGAGAGCATCCCCCTCCAGCCCCCGCAGGGCCCCGCCAGGGGCCCTCCAGAGCCCCCT
GTCCAGCTGCTGCAGCTCCTTCAGCTGGTCCAGCTTCTCCGAGGAGAGCTCCAGCCAGAAGGGC
GAGGACACCGGCACGTGCCAGGGGCTCCCGGACTCCGAGAGCTCCTTACCTACACCTGAC
GAGAAGGTGGCCGAGCTGGTGGAGTTCCTCCTGCTGAAGTACGAGGCCGAGGAGCCCGTCACC
GAGGCCGAGATGCTCATGATCGTGATCAAGTACAAGGACTACTTCCCCGTGATCCTGAAGCGCG
CCCGGGAGTTCATGGAGCTGCTCTTCGGCCTGGCGCTGATCGAGGTCGGGGCCCCGACCACTTCT
GCGTGTTGCCAACACGGTGGGCCTCACCGACGAGGGGAGCGACGACGAGGGCATGCCGGAG
AACTCCCTGCTGATCATCATCCTCAGCGTCATCTTCATCAAGGGCAACTGCGCCTCCGAGGAGGT
GATCTGGGAGGTGCTGAACGCCGTGGGGGTGTACGCGGGCCGCGAGCACTTCGTGTACGGGA
GCCCCGGGAGCTGCTACCAAGGTCTGGGTGCAGGGCCACTACCTGGAGTACCGCGAGGTGCC
GCACAGCTCCCCCCCCGTACTACGAGTTCCTGTGGGGCCCCCGGGCCACAGCGAGTCCATCAA
GAAGAAGGTCTCGAGTTCCTGGCCAAGCTGAACAACACCGTGCCAGCAGCTTCCCCTCCTGG
TACAAGGACGCCCTCAAGGACGTCGAGGAGCGCGTGACAGGCCACGATCGACACCGCGGACGAC
GCCACCGTGATGGCCAGCGAGTCCCTGAGCGTCATGTCCAGCAACGTGTCTTCAGCGAGTGAC
CACTAGTTATAAGACTGACTAGCCCGATGGGCCTCCCAACGGGCCCTCCTCCCCCTCCTTGACCC
GAGATTAATAA
AAAAAATATCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCTCTAGACAATTGGAATT

MRNA HsSTEAP(wt)-ag-A70

GGGAGACAAGCTTACCatggaaagcagaaaagacatcacaaaccaagaagaacttggaaaatgaagcctaggagaaatttag
aagaagacgattatttcataaggacacgggagagaccagcatgctaaaaagacctgtgcttttgattgcacaaacagcccagctgatg
aatttgactgcccctcagaactcagcacacacaggaactcttccacagtggcacttgccaattaaatagctgctattatagcatctctgactttc
ttacactctctgaggggaagtaattcacccttagcaacttcccatcaacaatattttataaaattccaatcctggtcatcaaaaagcttgccaat
ggttccatcactctctggcattggttacctgccagggtgtatagcagcaattgtccaacttcataatggaaccaagtataagaagttccacattg
gttgataagtgatgtaacaagaagcagtttgggctctcagtttcttttctgtactgcatgcaattatagctgtcttaccatgagggcat

cctacagatacaagttgctaaactgggcatatcaacagggtccaacaaaataagaagatgacctggattgagcatgatgtttggagaatggaga
ttatgtgtctctgggaattgtgggatggcaatactggctctgttgctgtgacatctatccaatctgtgagtgactctttgacatggagagaatttcaact
atattcagagcaagctaggaattgttcccttctactgggcacaatacacgcattgattttgacctggaataagtgatagatataaaacaattgtat
gggtatacacctccaactttatgatagctgtttcttccaattgtgtcctgatatttaaagcatactattcctgccatgcttgaggaagaagatactg
aagattgacatggttgggaagacgtcaccaaaattaacaaaactgagatatgtcccagttgtagCCACTAGTGACTIONGACTAGC
CCGCTGGGCCTCCCAACGGGCCCTCCTCCCCTCCTTGACCAAAAAAAAAAAAAAAAAAAAAAAAAA
AACTGCAGGTCGACTCTAGAGG
ATCCCCGGGTACCGAGCTCGAATT

MRNA HsSTEAP(GC)-muag-A70-C30

GGGagaAAGCTTaccATGgagagccggaaggacatcaccaaccaggaggagctgtggaagatgaagccgcgccggaacctcg
aggaggacgactacctgcacaaggacacggcgagacctgatgctgaagcggcccgctcctgcacctgcaccagaccgccacgcg
gacgagttcagctcccgagcgcagctccagcacacgcaggagctgttccgcagtgccacctgcccataagatcgccgccatcatcgca
gcctcaccttctgtacacctgtctccgcgaggtcatccaccgctggccacgtgcaccagcagttctacaagatcccgatcctggtgatc
aacaagggtgtcccatggtcagcatcacctgtgcccctgtgtacctgccccgggtgatcgccgcatcgccagctgcacaacggcacc
aagtacaagaagttcccgactggctcgacaagtggatgtgacgcggaagcagttcggcctgctcagcttcttctcgccgtgtgcacgcga
tctactcgtgagctacccatgcggcgcagctaccggtacaagctcctgaactgggcctaccagcaggtgcagcagaacaaggaggacgc
ctggatcgagcacgacgtctggcgatggagatctacgtgtcgtggtggatcgtggccctcgcatcctggccctgctcgccgtcaccagcatc
ccgagcgtgtcggacagcctgacctggcgaggtccactacatccagagcaagctgggcatcgtgtcgtcctgtctggggacgatccacgc
gctcatcttcgctggaacaagtggatcgacatcaagcagttcgtctggtacccccgccaccttcagatcgccgtgtcctgcccgatcgtgtt
cctgatctcaagagcatccttctcctgcccgtgcctgcggaagaagatcctcaagatccggcacggctgggaggacgtgacgaagatcaaca
agaccgagatctgcagccagctgtgaccACTAGTTATAAgactgactagcccgAtgggcctcccaacgggccctcctccctccttgca
ccgagAttaaTAAA
AAAAatattCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCtctagaCAATTGgaatt